Oswal Pumps commits ₹456 Cr to a captive solar-cell plant, redirecting almost all the remaining unutilised IPO proceeds earmarked for its manufacturing build-out

On Saturday evening, October 10, Oswal Pumps filed two announcements with the exchanges: the board of its wholly owned subsidiary Oswal Solar Energy Private Limited (OSEPL) approved a greenfield 1.2 GW solar-cell manufacturing plant at Karnal, Haryana, and the company's own board approved a variation in the objects of its IPO proceeds to help pay for it. The filings reached the exchange at 17:49 and 17:58 IST — after market close on a non-trading day — so the stock has not yet traded on this news.

Nearly all of the money being redirected comes from the ₹163.04 crore still unutilised under the Oswal Solar manufacturing object — not the IPO as a whole. Total unutilised IPO proceeds stand at ₹210.24 crore; the balance of roughly ₹47 crore, covering unutilised company capex and general corporate purposes funds, is untouched by this variation. The ₹163.04 crore of unutilised proceeds was originally earmarked for an Aluminium Frame Facility, the remaining 300 MW of an EVA Encapsulant Facility, and the remaining 500 MW of a Solar Module Facility. The filing argues all three are lower-value uses: frames are standardised components that can be bought from the market, the retained 1.2 GW of EVA capacity is described as largely sufficient, and the existing ~570 MW module line plus a 1 GW line now being set up are called sufficient for current requirements. Cells, by contrast, are described as the binding constraint — the point in the chain where supply and cost sit outside the company's control.

Why build rather than buy? The press release says the company evaluated long-term sourcing arrangements with established domestic cell manufacturers, including multi-year off-take commitments, and found the commercial terms — both pricing and upfront security-deposit requirements — not aligned with its assessment of long-term value or its approach to working capital. For a business the filing describes as anchored to DCR-dependent programmes like PM-KUSUM and PM Surya Ghar, that leaves both availability and cost of the key input outside the company's control. A comparative evaluation, per the filing, found captive cell manufacturing the more economically viable option — and with ALMM List-II compliance it protects the order-book eligibility those programmes require.

The strategic logic connects directly to the orders the company has been winning. Both of its recent disclosed wins are government-backed solar installations — exactly the DCR-dependent demand the filing says makes cell supply business-critical.

The orders have kept coming, but the P&L has softened. Q1 FY27 consolidated revenue of ₹473.6 crore was down 7.9% from ₹513.9 crore a year earlier, and net profit nearly halved — ₹54.1 crore against ₹94.7 crore, a 42.8% decline. The operating margin tells the sharper story: 15.7% in Q1 FY27 versus 27.4% in Q1 FY26. That context matters for reading the announcement, because the filing's central economic claim is that captive cells will strengthen the cost structure and improve consolidated profitability over time.

The market has already marked the stock down hard. Over the 60 sessions shown below it fell from ₹403.50 (July 16) to ₹254.35 (October 9) — about −37% — and the October 9 close sits roughly 1.2% above the 52-week adjusted low of ₹251.40 set the same day, and 67.8% below the 52-week adjusted high of ₹790 recorded on October 10, 2025. Institutional presence is thin: as of June 30, 2026, promoters held 75.65%, DIIs about 5.5% of shares, and FII holdings were negligible. The announcement landed on Saturday evening, so Monday's session is the market's first chance to price it.